Edit Optimization

De-risk editing strategies early to select approaches that scale to the clinic and manufacturing.

Talk To Us

True Single-Cell Knock-In Efficiency

Unpredictable insertion rates waste time, reagents, and cells.
Teams are working to avoid:
Endless optimization cycles

Failed experiments or batches

Low-yield manufacturing runs
Off-Target Editing and Missed Structural Changes

NGS alone may miss large or complex genomic alterations.
Teams are working to avoid:
Undetected structural variants

Regulatory red flags

Long-term safety risks
Uncontrolled Integration Patterns

Precision matters—teams want controlled location and copy number.
Teams are working to avoid:
Random integrations

Multi-copy insertions

Disruption of essential genes
Hidden Genomic Instability

Even “successful” edits can introduce:
Deletions

Duplications

Inversions

Translocations

Aneuploidy

Teams are working to avoid:
Cells with latent instability or risky phenotypes.
Late-Stage IND Failures

Poor genetic control often surfaces too late.
Teams are working to avoid:
Failed genotoxicity

Requests for additional genomic characterizations

Delayed commercialization
Manufacturing That Doesn’t Scale

Bench-scale success doesn’t guarantee commercial success.
Teams are working to avoid:
Shifts in editing performance at scale

Process-induced genomic artifacts

Batch-to-batch inconsistency